目的 探究紫龙金片联合GP方案治疗非小细胞肺癌的临床疗效。方法 选取2015年2月—2017年12月濮阳市油田总医院收治的非小细胞肺癌患者80例为研究对象，将所有患者随机分为对照组和治疗组，每组各40例。对照组给予GP化疗方案：第1、8天静脉滴注注射用盐酸吉西他滨，1.0 g/m²；第1天静脉滴注顺铂注射剂，60 mg/m²，4周为1个周期，2个周期为1个疗程。治疗组在对照组的基础上口服紫龙金片，4片/次，3次/d，连续治疗4周为1个周期，2个周期为1个疗程。两组患者均治疗1个疗程。观察两组的临床疗效，比较两组的生活质量、血清肿瘤标记物和不良反应。结果 治疗后，对照组和治疗组的有效率（RR）分别为30.0%、45.0%，疾病控制率（DCR）分别为67.5%、87.5%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的Karnofsky（KPS）评分提高率分别为37.5%、55.0%，两组比较差异有统计学意义（P<0.05）。治疗后，两组细胞角蛋-19片段（Cyfra21-1）、鳞癌相关抗原（SCC-Ag）水平显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清肿瘤标记物水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组白细胞减少发生率分别为70.00%、50.00%；红细胞减少发生率分别为52.50%、32.5%；血小板下降发生率分别为45.00%、30.00%；恶心呕吐发生率分别为82.50%、40.00%；腹泻发生率分别为37.50%、27.50%，两组不良反应发生率比较差异有统计学意义（P<0.05）。结论 紫龙金片联合GP方案治疗非小细胞肺癌具有较好的临床疗效，可改善患者生活质量，降低Cyfra21-1和SCC-Ag水平，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical study of Zilongjin Tablets combined with GP chemotherapy in treatment of non-small cell lung cancer. Methods Patients (80 cases) with non-small cell lung cancer in Puyang Oilfield General Hospital from February 2015 to December 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were given GP chemotherapy:intravenously injected Gemcitabine Hydrochloride for injection at the first and eighth day, 1.0 g/m², intravenously injected Cisplatin Injection at the first day, 60 mg/m², 4 weeks were 1 cycle and 2 cycles were 1 course. Patients in the treatment group were po administered with Zilongjin Tablets on the basis of the control group, 4 tablets/time, three times daily, 4 weeks were 1 cycle and 2 cycles were 1 course. Patients in two groups were treated for 1 course. After treatment, the clinical efficacies were evaluated, and the quality of life, serum tumor markers, and adverse reactions in two groups were compared. Results After treatment, the RR in the control and treatment groups were 30.0% and 45.0%, respectively, the DCR in the control and treatment groups were 67.5% and 87.5%, respectively, and there were difference between two groups (P < 0.05). After treatment, the KPS scores in the control and treatment groups were 37.5% and 55.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of Cyfra21-1 and SCC-Ag in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum tumor marker levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the incidence of leukopenia in the control and treatment groups were 70.00% and 50.00%, respectively; the red blood cells decreased incidence in the control and treatment groups were 52.50% and 32.5%, respectively; the incidence of thrombocytopenia in the control and treatment groups were 45.00% and 30.00%, respectively, the incidence of nausea and vomiting in the control and treatment groups were 82.50% and 40.00%, respectively, the incidence of diarrhea in the control and treatment groups were 37.50% and 27.50%, respectively, and there was difference between two groups (P < 0.05). Conclusion Zilongjin Tablets combined with GP chemotherapy has clinical curative effect in treatment of non-small cell lung cancer, can improve the quality of life, decrease the levels of Cyfra21-1 and SCC-Ag, with good safety, which has a certain clinical application value.